Physician profile
Danielle E Fernandes
NPI 1013228154
$814.76
in general payments reported to CMS, 2019-2025
14 companies · $158 in 2025
The $158 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $58.05 · 2021: $166 · 2022: $143 · 2023: $49.62 · 2024: $240 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $129.15 | 2020-2025 | Doc Band |
| Sanofi Pasteur INC. | $99.70 | 2021-2024 | |
| Glaxosmithkline, LLC. | $91.17 | 2022-2025 | Bexsero, Pediarix, Penmenvy |
| Takeda Pharmaceuticals U.S.A., INC. | $78.97 | 2020-2021 | |
| Pfizer INC. | $73.77 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $71.72 | 2021-2024 | M-M-R II, Vaxelis, Gardasil 9 |
| Hologic Sales and Service, LLC | $51.45 | 2025 | Aptima, Thinprep 2000 Processor |
| Alk-Abello, INC | $47.86 | 2025 | Neffy |
| Kaleo, INC. | $47.47 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $31.95 | 2024 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $25.99 | 2024 | |
| Noven Therapeutics, LLC | $24.31 | 2024 | Xelstrym |
| Ultragenyx Pharmaceutical INC. | $23.35 | 2022 | |
| Sobi, INC | $17.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Fernandes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.